Sequential methods and group sequential designs for comparative clinical trials

Fundamental and Clinical Pharmacology

Volumn 17, Issue 5, 2003, Pages 505-516

  Sébille, Véronique ^a   Bellissant, Eric ^a  

^a Inst de Rech Contre le Cancer IRCC   (France)

Author keywords

spending function; spending function; Group sequential designs; Interim analysis; Sequential probability ratio test; Triangular test

Indexed keywords

DRUG; PLACEBO;

ANALYSIS; BAYES THEOREM; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER PROGRAM; DATA ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG QUALITY; ECONOMIC ASPECT; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; MEDICAL ETHICS; MEDICAL INFORMATION; METHODOLOGY; MONITORING; POPULATION; PRIORITY JOURNAL; PROBABILITY; QUALITATIVE ANALYSIS; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; SAMPLE SIZE; SEQUENTIAL ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL; SURVIVAL;

ANIMALS; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS; HUMANS; MODELS, STATISTICAL;

EID: 0141816740     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00192.x     Document Type: Review

References (55)

1. Armitage P., McPherson C.K., Rowe B.C. Repeated significance tests on accumulating data. J. R. Statist. Soc. A (1969) 132 235-244.
2. Wald A. Sequential analysis. Wiley, New York. 1947.
3. Anderson T.W. A modification of the sequential probability ratio test to reduce the sample size. Ann. Math. Stat. (1960) 31 165-197.
4. Peto R., Pike M.C., Armitage P. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br. J. Cancer (1976) 34 585-612.
5. Pocock S.J. Group sequential methods in the design and analysis of clinical trials. Biometrika (1977) 64 191-199.
6. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics (1979) 35 549-556.
7. Whitehead J., Jones D.R. The analysis of sequential clinical trials. Biometrika (1979) 66 443-452.
8. Whitehead J., Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics (1983) 39 227-236.
9. Whitehead J. The design and analysis of sequential clinical trials. Ellis Horwood, Chichester. 1983.
10. Whitehead J. The design and analysis of sequential clinical trials. 2nd edn. Ellis Horwood, Chichester. 1992.
11. Whitehead J. The design and analysis of sequential clinical trials. Revised. 2nd edn. Wiley, Chichester. 1997.
12. Sébille V., Bellissant E. Comparison of the two-sided single triangular test to the double triangular test. Control. Clin. Trials (2001) 22 503-514.
13. Sébille V., Bellissant E. Letter to the Editor. Control. Clin. Trials (2002) 23 423-424.
14. Pocock S.J. Clinical trials: a practical approach. Wiley, Chichester. 1983.
15. Lan K.K.G., De Mets D.L. Discrete sequential boundaries for clinical trials. Biometrika (1983) 70 659-663.
16. Wang S.K., Tsiatis A.A. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics (1987) 43 193-199.
17. Emerson S.S., Fleming T.R. Symmetric group sequential test designs. Biometrics (1989) 45 905-923.
18. Pampallona S., Tsiatis A. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. J. Stat. Plann. Inf. (1994) 42 19-35.
19. Sébille V., Bellissant E. Comparison of four sequential methods allowing for early stopping of comparative clinical trials. Clin. Sci. (2000) 98 569-578.
20. Spiegelhalter D.J., Freedman L.S., Parmar M.K.B. Bayesian approaches to randomised trials. J. R. Statist. Soc. A. (1994) 157 357-416.
21. Rosner G.L., Berry D.A. A Bayesian group sequential design for a multiple arm randomized clinical trial. Stat. Med. (1995) 14 381-394.
22. Parmar M.K., Griffiths G.O., Spiegelhalter D.J., Souhami R.L., Altman D.G., van der Scheuren E. for the CHART steering committee. Monitoring of large randomised clinical trials: a new approach with Bayesian methods. Lancet (2001) 358 375-381.
23. Fisher L.D. Comments on Bayesian and frequentist analysis and interpretation of clinical trials. Control. Clin. Trials (1996) 17 423-434.
24. Saunders M.L, Dische S., Barrett A., Parmar M.K., Harvey A., Gibson D. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck non-small-cell lung cancer: an interim report. Br. J. Cancer (1996) 73 1455-1462.
25. Lan K.K.G., Simon R., Halperin M. Stochastically curtailed tests in long-term clinical trials. Comm. Stat. C (1982) 1 207-219.
26. Pepe M.S., Anderson G.L. Two-stage experimental designs: early stopping with a negative result. Appl. Stat. (1992) 41 181-190.
27. 0 embedded in sequential tests. Stat. Med. (1997) 16 465-477.
28. 0 based on conditional power: approximations and comparisons. Biometrics (1997) 53 794-806.
29. Snapinn S.M. Monitoring clinical trials with a conditional probability stopping rule. Stat. Med. (1992) 11 659-672.
30. Jennison C., Turnbull B.W. Statistical approaches to interim monitoring of medical trials: a review and commentary. Stat. Sci. (1990) 5 299-317.
31. Hardy R.J., Davis B.R., Palmer E.A., Tung B. Statistical considerations in terminating randomization in the multicenter trial of cryotherapy for retinopathy of prematurity. Control. Clin. Trials (1991) 12 293-303.
32. Lachin J.M., Lan S.P. Termination of a clinical trial with no treatment group difference: the lupus nephritis collaborative study. Control. Clin. Trials (1992) 13 62-79.
33. Peace K.E. One-sided or two-sided p values: which most appropriately address the question of drug efficacy? J. Biopharm. Stat. (1991) 1 133-138.
34. Overall J.E. A comment concerning one-sided tests of significance in new drug applications. J. Biopharm. Stat. (1991) 1 157-160.
35. Wolterbeek R. One and two sided tests of significance. Statistical hypothesis should be brought into line with clinical hypothesis. Br. Med. J. (1994) 309 873-874.
36. Knottnerus J.A., Bouter L.M. The ethics of sample size: two-sided testing and one-sided thinking. J. Clin. Epidemiol. (2001) 54 109-110.
37. Fleiss J.L. The design and analysis of clinical experiments. Wiley, New York. 1986.
38. Bland J.M., Altman D.G. One and two sided tests of significance. Br. Med. J. (1994) 309 248.
39. MPS Research Unit. PEST 4: operating manual. The University of Reading. Reading, 2000.
40. Cytel Software Corporation. EaSt. A software package for the design and interim monitoring of group-sequential clinical trials. Cytel Software Corporation. Cambridge, MA. 2000.
41. MathSoft inc. S-Plus. MathSoft Inc. Seattle, WA. 2000.
42. Gortner L., Pohlandt F., Bartmann P. et al. High-dose versus low-dose bovine surfactant treatment in very premature infants. Acta Paediatr. (1994) 83 135-141.
43. Packer M., O'Connor C.M., Ghali J.K. et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N. Engl. J. Med. (1996) 335 1107-1114.
44. Moss A.J., Hall W.J., Cannom D.S. et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhytmia. N. Engl. J. Med. (1996) 335 1933-1940.
45. Bellissant E., Duhamel J.F., Guillot M., Pariente-Khayat A., Olive G., Pons G. The triangular test to assess the efficacy of metoclopramide in gastroesophageal reflux. Clin. Pharmacol. Ther. (1997) 61 377-384.
46. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am. J. Ophtalmol. (1998) 126 498-505.
47. Cameron D.W., Heath-Chiozzi M., Danner S. et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet (1998) 351 543-549.
48. Lampeter E.F., Klinghammer A., Scherbaum W.A. et al. The Deutsche Nicotinamide Intervention Study. An attempt to prevent Type 1 diabetes. Diabetes (1998) 47 980-984.
49. Thomas R., Le Tulzo Y., Bouget J. et al. Trial of dexamethasone treatment for severe bacterial meningitis in adults. Intens. Care Med. (1999) 25 475-480.
50. Shaffer N., Chuachoowong R., Mock P.A. et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet (1999) 353 773-780.
51. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. (1999) 341 709-717.
52. Bergh J., Wiklund T., Erikstein B. et al. Tailored fiuorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet (2000) 356 1384-1391.
53. Packer M., Coats A.J., Fowler M.B. et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. (2001) 344 1651-1658.
54. Geller N.L., Pocock S.J. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Biometrics (1987) 43 213-223.
55. ICH E9 Expert Working Group. ICH Harmonised tripartite guideline: statistical principles for clinical trials. Stat. Med. (1999) 18 1905-1942.